Alexis Gutierrez, MD
Cardiovascular Disease · Hialeah, FLNPI 1700806106
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Merck at 36.6% of the total.
Across 221 payments — averaging $65.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5K
- Novartis$3K
- Eli Lilly$2K
- Medtronic$2K
- Janssen Research & Development, LLC$930
- Kestra Medical Technology Services, Inc.$263
- plus $865 from 14 others
Across 436 payments — averaging $18,599 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$6.6M
- Eli Lilly$707K
- Vifor (international) Ltd.$317K
- Janssen Research & Development, LLC$235K
- AstraZeneca$152K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$77K
- plus $30K from 3 others
What the payments were for
- Travel & lodging$7,99955%
- Food & beverage$6,54845%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 29 | $5,335 |
| Novartis | 80 | $2,857 |
| Eli Lilly | 37 | $2,422 |
| Medtronic(2 entities) | 21 | $1,888 |
| Janssen Research & Development, LLC | 9 | $930 |
| Kestra Medical Technology Services, Inc. | 1 | $263 |
| Coloplast | 1 | $151 |
| Johnson & Johnson | 8 | $123 |
| E.r. Squibb & Sons, L.L.C. | 7 | $122 |
| AstraZeneca | 6 | $93 |
| Lilly USA, LLC | 6 | $85 |
| GSK | 3 | $56 |
| Novo Nordisk | 3 | $45 |
| Boehringer Ingelheim | 2 | $41 |
| Abbott | 2 | $35 |
| Pfizer | 2 | $33 |
| Heartflow, Inc. | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Claria MRI$483
- LEQVIO$293
- Micra$276
- Assure WCD$263
- AZURE XT DR MRI SURESCAN$175
- Cobalt$165
- Reveal LINQ$155
- TITAN$151
- Azure$151
- EVERA MRI XT DR SURESCAN$150
- COBALT DR MRI SURESCAN$115
How this compares
$14,561 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 509 | $410,099 |
| EntrestoSacubitril/Valsartan | 390 | $334,991 |
| XareltoRivaroxaban | 235 | $199,011 |
| FarxigaDapagliflozin Propanediol | 233 | $169,727 |
| JardianceEmpagliflozin | 89 | $82,502 |
| MounjaroTirzepatide | 66 | $72,736 |
| TrulicityDulaglutide | 47 | $47,161 |
| RybelsusSemaglutide | 42 | $41,613 |
| BrilintaTicagrelor | 65 | $39,412 |
| OzempicSemaglutide | 36 | $38,571 |
| MultaqDronedarone Hcl | 28 | $32,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $29,548 |
| VascepaIcosapent Ethyl | 91 | $29,450 |
| Xigduo XrDapaglifloz Propaned/Metformin | 39 | $29,127 |
| JanuviaSitagliptin Phosphate | 39 | $25,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $410,099509 claims |
| NovartisEntresto | $2,857 | $334,991390 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $93 | $212,164311 claims |
| Johnson & JohnsonXarelto | $123 | $199,011235 claims |
| Lilly USA, LLCMounjaro, Trulicity | $85 | $119,897113 claims |
| Boehringer IngelheimJardiance, Pradaxa | $41 | $85,837107 claims |
| Novo NordiskRybelsus, Ozempic | $45 | $80,18478 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $38,32068 claims |
| MerckJanuvia, Janumet | $5,335 | $31,55850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hialeah
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.